Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal

References

• Mathers C, Boerma T, Ma Fat D. The global burden of disease: 2004 update. Geneva: World Health Organisation, 2008
   Google Scholar
• Wilkinson R, Pickett K. The spirit level: why equality is better for everyone. London: The Equality Trust, 2009. http://www.equalitytrust.org.uk/. Accessed July 7, 2015
   Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schiz Bull 2004;30:279-93
   PubMed Web of Science ®Google Scholar
• Karagianis J, Novick D, Pecanek J, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009;63:1578-88
   PubMed Web of Science ®Google Scholar
• Brissos S, Dias VV, Carita AI, et al. Quality of life in bipolar type I disorder and schizophrenia in remission: clinical and neurocognitive correlates. Psychiatry Res 2008;160:55-62
   PubMed Web of Science ®Google Scholar
• Brissos S, Dias VV, Balanzá-Martinez V, et al. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res 2011;129:133-6
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Binswanger IA, Penn JV, et al. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009;166:103-9
   PubMed Web of Science ®Google Scholar
• Glazer W, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in “revolving door” schizophrenic patients. J Clin Psychiatry 1996;57:337-45
   PubMed Web of Science ®Google Scholar
• Weiden P, Glazer W. Assessment and treatment selection for “revolving door” inpatients with schizophrenia. Psychiatr Q 1997;68:377-92
   PubMed Web of Science ®Google Scholar
• Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the “revolving door” phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-61
   PubMed Web of Science ®Google Scholar
• Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-7
   PubMed Web of Science ®Google Scholar
• Kane J, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Risperdal Consta® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Risperdal_Consta_30/WC500008170.pdf. Accessed July 7, 2015
   Google Scholar
• European Medicines Agency. Xeplion® opinion. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002105/WC500099946.pdf. Accessed July 7, 2015
   Google Scholar
• European Medicines Agency. Xeplion® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002105/WC500103317.pdf. Accessed July 7, 2015
   Google Scholar
• Alves da Silva E, Gouveia Pinto C, Sampaio C, et al. Guidelines for economic drug evaluation studies. Lisbon: INFARMED, 1998. http://www.ispor.org/PEguidelines/source/PE%20guidelines%20in%20English_Portugal.pdf. Accessed July 7, 2015
   Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry 2014;68:416-27
   PubMed Web of Science ®Google Scholar
• Martínez-Ortega JM, Gutiérrez-Rojas L, Jurado D, et al. Factors associated with frequent psychiatric admissions in a general hospital in Spain. Int J Soc Psychiatry 2012;58:532-5
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough D, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-56
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011;22:1-12
   Google Scholar
• Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol 2005;19:15-21
   PubMed Web of Science ®Google Scholar
• Lee M, Ko Y, Lee S, et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006;21:399-407
   PubMed Web of Science ®Google Scholar
• Olivares J, Rodrigues-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Lindenmayer J-P, Khan A, Eerdekens M, et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007;17:138-44
   PubMed Web of Science ®Google Scholar
• Quraishi SN, David A, Brasil MA, et al. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev 1999;Issue 1:CD001361
   Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;Issue 3:CD006654
   Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107-17
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072-82
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer J-P, Lull JM. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-44
   PubMed Web of Science ®Google Scholar
• Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2006;Issue 2:CD005237
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Lindenmayer JP, Kwentus J. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr Res 2014;154:14-22
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-17
   PubMed Web of Science ®Google Scholar
• Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70:91-100
   PubMed Web of Science ®Google Scholar
• Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010;25:685-97
   PubMed Web of Science ®Google Scholar
• Hough D, Lindenmayer J-P, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022-31
   PubMed Web of Science ®Google Scholar
• Weiden P, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
   PubMed Web of Science ®Google Scholar
• Mehnert A, Diels J. Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry -Mental Health Policy and Economics; 25-27 March 2011, Venice, Italy
   Google Scholar
• Bartkó G, Herceg I, Zador G. Clinical symptomatology and compliance in schizophrenia patients. Acta Psychiatr Scand 1988;77:74-6
   PubMed Web of Science ®Google Scholar
• Heyscue BE, Levin GM, Merrick JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998;49:1232-4
   PubMed Web of Science ®Google Scholar
• Guo X, Fang M, Zhai J, et al. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl) 2011;216:475-84
   PubMed Web of Science ®Google Scholar
• Hamilton SH, Revicki DA, Edgell RT, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial. Pharmacoeconomics 1999;15:469-80
   PubMed Web of Science ®Google Scholar
• Yu AP, Ben-Hamadi R, Birnbaum HG, et al. Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. Curr Med Res Opin 2009;25:755-64
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries D, Zhu B. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;2006:453-60
   Google Scholar
• Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-9
   PubMed Web of Science ®Google Scholar
• Briggs A, Wild D, Lees M. Impact of schizothrenia and schijophrenia treatmeft-related adverse events on qua,ity of mife: direct utimitx elicitation. Health Qual Life Outcomes 2008;6:105
   PubMed Web of Science ®Google Scholar
• Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee Report. Birmingham, UK: Department of Public Health & Epidemiology, University of Birmingham; 1998
   Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schiz Res 2004;71:155-75
   PubMed Web of Science ®Google Scholar
• Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137-56
   Google Scholar
• Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101-8
   PubMed Web of Science ®Google Scholar
• Rittmannsberger H, Pachinger T, Keppelmuller P, et al. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 2004;55:174-9
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001;62:545-51
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia Patient Prefer Adherence 2008;2:67-77
   Google Scholar
• Portugal inflation rate (consumer prices). http://www.indexmundi.com/portugal/inflation_rate_(consumer_prices).html. Accessed April 17, 2015
   Google Scholar
• Ministério da Saúde. Portaria n.° 20/2014, de 29 de Janeiro. Diário da República, 1.a série — N.° 20. http://www.acss.min-saude.pt/Portals/0/DownloadsPublicacoes/Tabelas_Impressos/Portaria%20132_2014.pdf. Accessed June 15, 2015
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics 2013;31:361-7
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26:733-44
   PubMed Web of Science ®Google Scholar
• European Central Bank. Exchange rates pound. https://www.ecb.europa.eu/stats/exchange/eurofxref/html/eurofxref-graph-gbp.en.html. Accessed June 15, 2015
   Google Scholar
• Yazdanpanah Y, Perelman J, DiLorenzo MA, et al. Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One 2013;8:e84173
   PubMed Web of Science ®Google Scholar
• Ferreira L, Belo A, Cassiano Abreu-Lima C. A case-control study of cardiovascular risk factors and cardiovascular risk among patients with schizophrenia in a country in the low cardiovascular risk region of Europe. Rev Port Cardiol 2010;29:1481-93
   PubMedGoogle Scholar
• Lambert M, De Marinis T, Pfeil J, et al. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry 2010;25:220-9
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry 2014;68:416-27
   PubMed Web of Science ®Google Scholar
• Einarson TR, Pudas H, Zilbershtein R, et al. Pharmacoeconomic analysis of atypical antipsychotic depots for chronic schizophrenia in Finland J Med Econ 2013;16:1096-105
   PubMedGoogle Scholar
• Jukic V, Jakovljevic M, Filipcic I, et al. Cost-utility analysis of depot antipsychotics for chronic schizophrenia in Croatia. Value Health Reg J Central East Europe 2013:181-8
   Google Scholar
• Einarson TR, Zilbershtein R, Skoupá J, et al. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. J Med Econ 2013;16:1089-95
   PubMedGoogle Scholar
• Garrido P, Pereira C, Craveiro A. Atypical antipsychotics versus first generation antipsychotics: comparison of overall efficacy and costs in a Portuguese sample. Abstract P.3.c.044. Eur Neuropsychopharmacol 2011;21(3 Suppl):S493-S4
   Google Scholar
• Heeg BM, Buskens E, Vaz Serra A, et al. Costs and effects of Risperdal Consta in comparison to conventional depot and short-acting atypical formulations in Portugal. Value Health 2004;7:778
   Web of Science ®Google Scholar
• Heeg BM, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Curr Med Res Opin 2008;24:349-58
   PubMed Web of Science ®Google Scholar
• Schizophrenia. The NICE guidelines on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated edition. National Clinical Guideline Number 82. London: National Institute for Health and Clinical Excellence, 2010
   Google Scholar
• Rosenheck R, Massari L, Astrachan BM. The impact of DRG-based budgeting on inpatient psychiatric care in Veterans Administration medical centers. Med Care 1990;28:12-34
   Web of Science ®Google Scholar
• Frick U, Barta W, Binder H. [Hospital financing in in-patient psychiatry via DRG-based prospective payment–The Salzburg experience]. Psychiatr Prax 2001;28(1 Suppl):S55-62
   Google Scholar
• Rosenheck R, Massari L. Psychiatric inpatient care in the VA: before, during, and after DRG-based budgeting. Am J Psychiatry 1991;148:888-91
   PubMed Web of Science ®Google Scholar
• Einarson TR, Pudas H, Goswami P, et al. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. J Med Econ 2016;19:111-20
   PubMed Web of Science ®Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics 2016;34:363-91
   PubMed Web of Science ®Google Scholar
• Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 2015;169:393-9
   PubMed Web of Science ®Google Scholar
• Alphs L, Mao L, Lynn Starr H, et al. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia. Schizophr Res 2016;170:259-64
   PubMed Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-World outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry 2015;76:554-61
   PubMed Web of Science ®Google Scholar
• Schreiner A, Bergmans P, Cherubin P, et al. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. J Psychopharmacol 2015;29:910-22
   PubMed Web of Science ®Google Scholar
• Schreiner A, Bergmans P, Cherubin P, et al. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents. Clin Ther 2014;36:1372-88.e1
   PubMed Web of Science ®Google Scholar
• Alphs L, Bossie CA, Sliwa JK, et al. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. Neuropsychiatr Dis Treat 2013;9:341-50
   PubMed Web of Science ®Google Scholar